July, 2026.- Most strategists hear data and look for proof. Elise Pietracatella hears data and looks for the human story underneath it. Those are very different instincts, she explains, and they lead to very different work.
At AbelsonTaylor Group, Pietracatella sits at the intersection of scientific credibility and human truth. She helps life science brands figure out not just what they want to say, but why it matters to the people they are trying to reach. A clinical trial result alone does not move a physician. It informs them. But when you understand what genuinely keeps them up at night and then bring them the data that speaks directly to that fear? Everything changes. That is not a communications trick. That is empathy applied with precision.
In this interview, Pietracatella discusses where most healthcare strategists get the balance wrong between clinical rigor and human insight. The science and the soul of a product are one conversation—not two tracks running parallel. Not clinical rigor first, human insight bolted on at the end. One conversation from the very beginning. Because the data is always trying to tell a human story. Most people just do not know how to hear it.
Pietracatella also reflects on her belief that the brief is just the beginning—and that is where a lot of the magic gets lost. The strategist writes something brilliant, hands it over the wall, and hopes it survives contact with the real world. Most of the time, it does not fully. She sees herself as a creative collaborator first and a briefer second. That means she is in the room when the ideas are being shaped, asking the same questions she asked at the start. In healthcare, the stakes are too high to let strategy and creativity drift apart mid-process.
On fostering psychologically safe team environments, Pietracatella notes that fear of challenging the status quo makes you hedge the strategy. Fear of regulatory makes you shrink the idea. Fear of being wrong makes you default to what has been done before. Before you know it, you have a room full of smart, talented people producing work that is safe for everyone except the person who actually needed that medicine to change their life. When fear leaves the room, curiosity takes over. Curious teams ask better questions. They find sharper insights and build braver, more distinctive work.
1. Clinical Data + Human Behavior: You’re known for translating complex clinical data into compelling brand strategies. Where do most healthcare strategists get the balance wrong between clinical rigor and human insight?
It comes down to listening differently.
Most strategists hear data and look for proof. I hear data and look for the human story underneath it. Those are very different instincts. And they lead to very different work.
Here’s what I know. A clinical trial result alone doesn’t move a physician. It informs them. It doesn’t move them. But when you understand what genuinely keeps them up at night, and then bring them the data that speaks directly to that fear? Everything changes.
That’s not a communications trick. That’s empathy applied with precision.
At AbelsonTaylor Group we’ve always believed the science and the soul of a product are one conversation. Not two tracks running parallel. Not clinical rigor first, human insight bolted on at the end. One conversation. From the very beginning.
Because the data is always trying to tell a human story. Most people just don’t know how to hear it.
That’s the role we play for our life science partners. We sit at the intersection of scientific credibility and human truth. We help brands figure out not just what they want to say, but why it matters to the people they’re trying to reach.
That’s a different conversation than traditional agency work. Fundamentally different.
And when you get it right, something shifts. A brand stops being a product. It becomes something that genuinely changes how people live.
That’s the work worth doing. And at Abelson Taylor, that’s what we show up for every day.
2. Creative-Backed Planning: Your background uniquely blends strategic rigor with creative instinct. Does the planner’s job end when the brief is written, or should strategists stay embedded through execution?
Honestly, the brief is just the beginning.
And that’s where a lot of the magic gets lost.
The strategist writes something brilliant. Hands it over the wall. Hopefully it survives contact with the real world. Most of the time, it doesn’t. Not fully. And nobody says anything because the brief was good and the creative looks fine and the client seems happy.
But fine isn’t the same as true.
I see myself as a creative collaborator first and a briefer second. That means I’m in the room when the ideas are being shaped, asking the same questions I asked at the start. Does this still speak to the human truth we uncovered? Does it honor the science while making someone feel something?
Because in healthcare, the stakes are too high to let strategy and creativity drift apart mid-process.
And I mean that literally. Life science brands invest years and billions of dollars bringing a product to market. The science is extraordinary. The clinical need is real. But we’ve all seen what happens when that story never connects with the physician or patient it was meant to reach.
A treatment that could change lives ends up sitting on the shelf, because the communication didn’t land. That’s not a creative failure. That’s a human one.
That’s exactly the gap we exist to close at AbelsonTaylor Group. When strategy stays embedded through execution, when the human truth is protected all the way to the final frame, brands don’t just show up in the market. They show up with conviction. That’s when life science brands don’t just compete. They win.
3. Psychologically Safe Planning: You’re recognized for fostering “psychologically safe team environments.” In a high-stakes healthcare category, what’s the biggest barrier to candid strategic thinking—fear of the client, fear of regulatory, or fear of being wrong?
Honestly, it’s all three. And they don’t show up separately. They feed each other.
Fear of challenging the status quo makes you hedge the strategy. Fear of regulatory makes you shrink the idea. Fear of being wrong makes you default to what’s been done before. And before you know it, you’ve got a room full of smart, talented people producing work that’s safe for everyone except the person who actually needed that medicine to change their life.
In our work, psychological safety isn’t a nice to have. It’s a deliberate practice. The boldest, most honest thinking has to be able to surface and survive. From the first briefing all the way through to final execution. That means creating space where anyone in the room can challenge an assumption, push back on a direction, or say ‘I don’t think this is right.’
Most agencies hope that happens. We build for it. When fear leaves the room, curiosity takes over. Curious teams ask better questions. They find sharper insights and build braver, more distinctive work that actually moves markets.
For life science brands trying to break through in one of the most complex, regulated, and deeply human categories in the world, that’s the partner you want in your corner.
4. Immunology, Oncology, Payer: You’ve led strategy across immunology, oncology, and payer audiences. Which of these is hardest to humanize, and what did you learn there that applies to the others?
Payers. Without question. And that answer alone usually starts an interesting conversation.
Most strategists brief payers as a purely rational audience. Budget driven.
Outcomes focused. All spreadsheet, no soul. And the work shows it. Technically correct.
Completely forgettable.
But here’s what behavioral economics taught me. Even the most data driven decision maker feels before they rationalize. Loss aversion. Status quo bias. Social proof. It’s all there. The language is different, but the humanity underneath is the same.
And when you stop treating payers like calculators and start treating them like people, something unexpected happens.
You find a person who got into healthcare for a reason. Someone who believes in access. Someone who understands that the wrong coverage decision has a real face attached to it.
When you find that truth, everything shifts. You’re not just making a business case anymore. You’re making a case that moves people to act differently.
In immunology, it’s finding the invisible burden behind a condition the world doesn’t always take seriously. In oncology, it’s holding space for both the clinical urgency and the deeply personal journey of every patient and physician.
No audience is purely rational. Not payers. Not physicians. Not patients. Everyone has a human truth waiting to be found.
Every audience. Every category. Every brief. Because when you build strategy around that truth, life science brands show up with purpose. That’s when they win.
5. Independent Consultant Back to Agency: You returned to agency leadership after working as an independent consultant. What did you learn about strategy while working alone that you couldn’t have learned inside an agency?
There’s a moment when you’re on your own, no team, no safety net, no process to fall back on, where you find out what you’re actually made of as a strategist.
What consulting forced me to do was uncomfortable. Lead with curiosity instead of convention. Trust instinct over process. Stop asking what’s been done before. Start asking what this brand actually needs to become. That’s a different question entirely. And most agencies never get there.
But the bigger revelation wasn’t about me. It was what I heard sitting on the other side of the table. Life science brands don’t just want an agency that’s smart. They’ve had smart. Smart doesn’t move markets. Smart doesn’t change lives.
They want a partner genuinely invested in their success. Someone who understands the science, feels the urgency, and brings a point of view that travels with their brand. Not just at the brief. Not just at the presentation. At every moment in between.
That passion for client outcomes, not just the brief, not just the work, but the actual impact on a brand’s success, that’s what a good pharma ad agency is built around. That’s what drew me to AT Group. Advancing our mission to “help the world choose better health” feels like exactly where I’m supposed to be.
6. Patient Impact as a Metric: You’ve volunteered as Corporate Chair for the Arthritis Foundation’s Walk to Cure. How does personal commitment to patient impact change the way you judge strategic success compared to a planner without that lived connection?
Here’s the thing about sitting across from someone living with arthritis. You stop thinking in market share. You stop thinking in reach and frequency. You start thinking about whether the work you’re doing is actually changing something real for someone real.
That’s what volunteering does. It makes the abstract, concrete. Every data point has a face. Every insight has a name. And once you see that, you can’t unsee it.
Most planners celebrates when the numbers move. I want to know whose life was moved by them.
I ask whether the right person felt seen. Whether a physician understood something they didn’t before. Whether a patient got access to something that changed their day. That’s a different scorecard entirely. And that’s not a soft metric. That’s the hardest one there is.
At AbelsonTaylor Group we take that seriously enough to build it into the culture itself. HeartsATWork is our employee-driven CSR program. We have over 50 opportunities a year for our people to donate their time, skills and energy to causes that matter. Lurie Children’s Hospital. Global nutrition initiatives. Youth violence prevention. Patient advocacy organizations.
Because patient commitment shouldn’t live only in the brief. It should live in the people writing it.
The patients on the other end of our work aren’t waiting for us to get it right eventually. They need us to get it right now. That’s the standard I hold myself to. And the standard we hold ourselves to for every life science brand we partner with.
